摘要:
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat tumors having neuroendocrine features are provided.
摘要:
The present invention provides a method for using non-human animals to mimick human clinical trial comprising: (a) obtaining cells or tissues from n human subjects suffered from a disease, wherein n>1; (b) establishing a control group and a treatment group, wherein i) the control group comprises i control non-human animals, wherein i≧n, wherein cells or tissue from each human subject are grafted to at least one control non-human animal; ii) the treatment group comprises j treatment non-human animals, wherein j≧n, wherein cells or tissue from each human subject are grafted to at least one treatment non-human animal; and iii) each control non-human animal or treatment non-human animal is grafted with cells or tissues from one human subject; (c) administering a first agent to the control group and administering a second agent to the treatment group, wherein the first agent is different from the second agent; (d) obtaining the end point of the control group and the treatment group; and (e) comparing the end point of the control group to the end point of the treatment group.
摘要:
Provide are novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat recurrent tumors and to reduce or inhibit tumor recurrence in a subject.
摘要:
It is intended to disclose an antibody which binds to DLL3 protein. Preferably, the antibody of the present invention recognizes a region from amino acids 216 to 492 in human DLL3 having the amino acid sequence as set forth in SEQ ID NO: 1. The present invention also provides a pharmaceutical composition, for example, an anticancer agent, comprising the antibody of the present invention as an active ingredient. The present invention further discloses a method for diagnosing cancer using the antibody of the present invention and a diagnostic drug for cancer comprising the antibody of the present invention.
摘要翻译:旨在公开结合DLL3蛋白的抗体。 优选地,本发明的抗体识别具有SEQ ID NO:1所示的氨基酸序列的人DLL3中的氨基酸216至492的区域。本发明还提供药物组合物,例如抗癌剂 ,其包含本发明的抗体作为活性成分。 本发明还公开了使用本发明的抗体和包含本发明的抗体的癌症诊断药物诊断癌症的方法。
摘要:
Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
摘要:
The present invention relates to RSPO-binding agents and methods of using the agents for treating diseasesF such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
摘要:
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
摘要:
The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer, for monitoring the effectiveness of cancer, such as bladder cancer, esophagus cancer, head and neck cancer, lung cancer, pancreatic cancer, gastric cancer, uterine cancer, cervical cancer, skin cancer and breast cancer treatment, and for drug development.
摘要:
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
摘要:
The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
摘要翻译:本发明涉及包含与抗体或抗原结合抗体片段连接的SN-38的治疗性免疫偶联物。 抗体可以结合EGP-1(TROP-2),CEACAM5,CEACAM6,CD74,CD19,CD20,CD22,CSAp,HLA-DR,AFP或MUC5ac,免疫缀合物可以以4mg / kg 和24mg / kg,优选4,6,8,9,10,12,16或18mg / kg。 当以特定的剂量和时间表施用时,免疫缀合物可以减少实体肿瘤的大小,减少或消除转移,并且有效治疗对标准疗法(例如放射治疗,化疗或免疫治疗)具有抗性的癌症。